AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|
23.6 C
New York
Saturday, July 25, 2026

Tag: cancers

newssourceFORcompanyinformationcontent1releasesmarket

GRAL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges that Grail’s top executives made false and/or misleading statements to investors.

The Inner Circle acknowledges, Michael M. Pennock, MD, MBiot, DABR as a Pinnacle Lifetime Member

BEAVER, Pa., June 12, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Michael M. Pennock, MD, MBiot, DABR is recognized as a Pinnacle Lifetime...

PROCURE PROTON THERAPY CENTER CELEBRATES JOSEPH AS ITS 8,000TH PATIENT

SOMERSET, N.J., June 12, 2026 /PRNewswire/ -- When Joseph, a military veteran diagnosed with prostate cancer, became ProCure Proton Therapy Center's 8,000th patient, the milestone...

Allegheny Health Network’s Biomarker Moonshot Cancer Research Program Marks Five-Year Milestone, Enrolling More Than 11,000 Patients Across All Cancer Types

Systemwide research initiative uses blood‑based genomics to improve early detection and personalize cancer treatmentPITTSBURGH, June 12, 2026 /PRNewswire/ -- Allegheny Health Network (AHN) Cancer...

SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

TAIPEI, Taiwan, June 12, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. (“SL Bio” or the “Company”), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced the closing of its previously announced business combination with Horizon Space Acquisition II Corp. (Nasdaq: HSPT) (“Horizon Space”), a publicly traded special purpose acquisition company.

/C O R R E C T I O N — Melanoma Research Alliance/

In the news release, LEVERAGED FINANCE FIGHTS MELANOMA RAISES RECORD $4.3 MILLION FOR THE MELANOMA RESEARCH ALLIANCE, issued 11-Jun-2026 by Melanoma Research Alliance over...

Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis

Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis

Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer

Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer

Matter Bio Announces FDA Clearance of IND Application for LM-LLO-TT in Pancreatic Ductal Adenocarcinoma

FDA clearance enables initiation of first-in-human Phase 1/2a clinical trial evaluating LM-LLO-TT, Matter Bio's attenuated Listeria monocytogenes-based immunotherapy candidate.SAN FRANCISCO, June 10, 2026 /PRNewswire/ --...

Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company

Minami Maeda appointed as CEO to drive faster, more focused execution toward U.S. commercial launchMickey Mikitani will continue to provide strategic direction and remains...

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancers

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers